The global aptamer market was valued at approximately US$ 1.0 Bn in
2016 is projected to register cumulative annual growth rate (CAGR) of
over 20.0% from 2017 to 2025, according to a new report published by
Transparency Market Research (TMR) titled “Aptamer Market –
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast,
2017–2025”. The report suggests that surge in interest of
research activity in the field of aptamer technology is likely to
spur the demand of aptamer in the coming years (2017 to 2025). As key
players introduce their new aptamer services for different
application in developed markets such a North America and Western
Europe, these regions are likely to account for dominating share of
the global aptamer market. Demands for new diagnostic assay and
increasing research activity in emerging markets such as China and
Japan is likely to boost growth of Asia Pacific aptamer market at a
CAGR of around 21.0% from 2017 to 2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335
Inadequate Regulatory Policies and Ethical Issues Related To
Aptamer Development Can Restrain Global Market Expansion
Aptamer can be used as alternative to antibodies for various
application. There is no formal regulatory guideline, which
specifically addresses the quality expectation of aptamers. The
regulatory expectation of aptamer-based drugs is still evolving.
Several countries in Europe have tedious documentation processes for
starting clinical trials of aptamers. For example, in Europe, the EU
Clinical Trial Directive 2001/20/ EC is mandatory for initiation of
aptamer clinical trials. However, the region has not developed any
oligonucleotide specific guideline that can address the general
requirements for the quality of aptamer clinical trials. Moreover,
lack of universal rules for the application of aptamers in bioassays,
which is well established when working with antibodies, restrains
growth of global aptamer market.
Other Selection
Techniques (e.g. X- Aptamer, MARAS etc.) to Lose Market Share
The report offers detailed segmentation of global aptamers market
based on material type, selection technique and applications. Among
the selection technique studied, SELEX technique segment is poised to
account for leading share of the global market during the forecast
period from 2017 to 2025. SELEX technique is likely to get boost for
the modification of existing SELEX process, and available of the new
updated SELEX technique like CE-SELEX, M- SELEX etc. which overcome
the certain limitation for aptamer selection. The other technique
(X-aptamer, MARAS technique etc.) segment is anticipated to lose its
market share during the forecast period, and is expected to hold a
share of ~18.0% by 2025 from ~21% in 2016. Availability of upgraded
SELEX technique and lack of selection of high affinity ligands as
compare to SELEX technique are factors likely to hamper this
segment.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1335
Diagnostics & Research: Top Two Application Areas of Aptamer
Among applications, research segment is projected to hold dominant
share of global aptamer market during the forecast period and is
likely to expand at CAGR more than 21.0% from 2017 to 2025. Major
factors responsible for the dominance of this segment are efforts by
several key players to develop new aptamers for research and
development applications. For example, Aptagen, LLC has developed
aptabodies (patent pending) that overcome the limitation of
traditional pharmaceutical drug discovery process. The Aptabody
technology demands shorter development time and offers effective
Adsorption, Distribution, Metabolism and Excretion (ADME) properties
due to unique chemical properties. Aptabodies are formed by
hybridization of two DNA aptamers and allow detection of human
thrombin effectively compared to traditional aptamers. In addition,
aptabodies represent new area of development for next generation
pharmaceuticals with improved pharmacokinetics and pharmacodynamic.
Diagnostics segment, accounted for more than 30.0% share of global
aptamer market in 2016, in terms of value. It is anticipated to have
substantial growth and account for approximately 33.8% of market
share by 2025.
Asia Pacific to Resister Exponential Growth and Offer Huge
Incremental Opportunity
In terms of value, North America was leading contributor in global
aptamer market in 2016. High level of research activity in the U.S.
is one of the contributing factor for major share of the North
America market. Furthermore, presence of several key players such as
Aptagen, Inc., Regado Biosciences, Inc. and Somalogic, Inc. has
resulted in increased investment in research and development of novel
aptamers. Thus, presence of these players would help the aptamers
market in North America to grow rapidly during the forecast period
Pharmaceutical research and development spending in emerging markets
such as China and India are rising, which is fueling the expansion of
Asia Pacific aptamer market. Regaining economic growth in Latin
American markets such as Brazil is augmenting research and
development activity, spending is increasing in diagnosis and
treatment of various diseases in this region. This factor is likely
to propel Latin America cardiovascular drugs market at CAGR of 19.0%
from 2017 to 2025.
Request for the TOC of the Report @
https://www.transparencymarketresearch.com/report-toc/1335
Key Players such as Somalogic, Inc., Aptagen, Inc, and Aptamer Group
Limited are Likely to Continue to Lead the Global Aptamer Market
The report also provide profiles of leading players operating in
global aptamer market include AM Biotech, Aptagen, LLC., Aptamer
Group, Aptamer Sciences, Inc., Base Pair Biotechnologies, CD
Genomics, NeoVentures Biotechnology Inc., NAXXON Pharma, Aptus
Biotech, TriLink BioTechnologies, LLC., and Pfizer Inc. Expansion of
aptamer based products portfolio through improving existing drugs and
developing new drug molecules is one of the key strategy adopted by
many key players, recent developing drugs such as NOX-E36 for
treating type 2 diabetes by NAXXON Pharma and other key players
reflect these strategies.
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
No comments:
Post a Comment